💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadExplore for free

3 Red-Hot Rocket Stocks to Buy Right Now

Published 2018-10-22, 12:30 p/m
3 Red-Hot Rocket Stocks to Buy Right Now

Hello again, Fools. I’m back to highlight three stocks that have recently risen to new 52-week highs. As a reminder, I do this because rising stock prices

  • are usually driven by an improvement in fundamentals (what we care about most here at The Fool); and
  • tend to attract even more attention from buyers over the short term.
Valuation still matters, of course. But as long as you’re careful not to pay too high of a price, quality momentum plays can provide satisfying gains.

So, without further ado, let’s get to this week’s red-hot ideas.

Rental income riches

Leading off our list is InterRent REIT (TSX:IIP.UN), whose shares hit a 52-week high of $12.27 on Friday. Over the past year, the multi-residential REIT is up an impressive 45% versus a gain of just 6% for the S&P/TSX Capped REIT Index.

InterRent continues to benefit from strong demand in its key markets. In Q2, net operating income spiked 25% to $20 million on a 17% increase in gross rental revenue. More importantly, funds from operations (FFO) — the key cash flow metric for REITs — clocked in at $10.9 million, a 31% jump over the year-ago period.

Thanks to that strength, management upped its distribution 11%. With the stock still sporting a decent yield of 2.3%, along with a comforting beta of 0.4, InterRent’s downside looks limited even at these elevated levels.

Healthy momentum

Next up we have Viemed Healthcare (TSX:VMD), which managed to reach a 52-week high of $8.75 last week. Shares of the healthcare equipment specialist have gained a whopping 228% year to date, while the S&P/TSX Capped Health Care Index is up 36% over the same time period.

Viemed is adding patients to its therapy at a breakneck pace. In Q2, revenue spiked 42% to $15.5 million as its ventilator patient count jumped 35%. Meanwhile, gross margin expanded 44%, suggesting that its cost structure and competitive position are also improving. That performance is especially impressive given Viemed’s rock-solid balance sheet.

Looking forward, management expects Q3 revenue growth of about 33% on similar margins.

The stock isn’t dirt cheap after the monstrous run-up. But at a forward P/E of 24, Viemed’s solid growth prospects remain priced very reasonably.

Golden gainer

Finally, we have Wesdome Gold Mines (TSX:WDO), whose shares climbed to a 52-week high of $4.18 on Friday. The small-cap gold miner has more than doubled over the past six months, while the S&P/TSX Capped Materials Index is down 8% during the same time period.

Wesdome’s production continues to blow Bay Street estimates out of the water. Earlier this month, management announced that year-to-date production now stands at 54,371 ounces. The company is well positioned to achieve its raised guidance range of 70,000-75,000 for the current quarter. In other words, Wesdome’s production is more than offsetting the weak price of gold.

When you couple that positive operating momentum with a rock-solid financial position — Wesdome has zero debt on its balance sheet — the stock’s risk/reward tradeoff remains attractive.

Fool on.

Brian Pacampara owns no position in any of the companies mentioned. Viemed is a recommendation of Hidden Gems Canada.

This Article Was First Published on The Motley Fool

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.